Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults ...Middle East

TITUSVILLE, N.J., Nov. 2, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate 6-month (PP6M) for the...

Hence then, the article about janssen submits paliperidone palmitate 6 month pp6m supplemental new drug application to u s fda for treatment of schizophrenia in adults was published today ( Monday 02/11/2020 - 03:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults )

Also on site :

• As Trump Bombs Iran, America’s Allies Watch Fitfully From Sidelines
• Israel And Hezbollah Exchange Fire As Middle East Conflict Widens
• British military base in Cyprus targeted in suspected drone attack